Datum Källa Rubrik Typ Alternativ
2023-05-23 Asarina Pharma Positive Tourette Syndrome results to be presented at ESSTS, 15th European Conference on Tourette Syndrome and Tic Disorders Pressreleaser Ladda ner | Visa Stäng
2023-05-22 Asarina Pharma Kommuniké från årsstämma i Asarina Pharma AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-05-22 Asarina Pharma Bulletin from the Annual General Meeting of Asarina Pharma AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-05-05 Asarina Pharma Asarina Pharma's positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America Pressreleaser Ladda ner | Visa Stäng
2023-04-28 Asarina Pharma Asarina Pharma AB (publ) releases Annual Report 2022 Pressreleaser Ladda ner | Visa Stäng
2023-04-28 Asarina Pharma Asarina Pharma AB (publ) årsredovisning 2022 publicerad Pressreleaser Ladda ner | Visa Stäng
2023-04-18 Asarina Pharma Asarina Pharma: KALLELSE TILL ÅRSSTÄMMA I ASARINA PHARMA AB (PUBL) Pressreleaser Ladda ner | Visa Stäng
2023-04-18 Asarina Pharma Asarina Pharma: NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL) Pressreleaser Ladda ner | Visa Stäng
2023-04-01 Asarina Pharma Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome Pressreleaser Ladda ner | Visa Stäng
2023-04-01 Asarina Pharma Asarina Pharma publicerar positiva resultat från sin fas IIa-studie av Sepranolon i Tourette syndrom Pressreleaser Ladda ner | Visa Stäng
2023-02-27 Asarina Pharma Asarina Pharma AB (publ) släpper bokslutskommuniké för 2022 Rapporter Ladda ner | Visa Stäng
2023-02-27 Asarina Pharma Asarina Pharma AB (publ) releases Year-End Report 2022 Rapporter Ladda ner | Visa Stäng
2023-02-02 Asarina Pharma Asarina Pharma: Sista patientens sista besök i Tourette syndrom-studien Pressreleaser Ladda ner | Visa Stäng
2023-02-02 Asarina Pharma Asarina Pharma: Last Patient Last Visit for landmark Tourette Syndrome study Pressreleaser Ladda ner | Visa Stäng
2022-10-14 Asarina Pharma Asarina Pharma: Full rekrytering och sista patienten randomiserad i den viktiga studien om Tourettes syndrom Pressreleaser Ladda ner | Visa Stäng
2022-10-14 Asarina Pharma Asarina Pharma: Patient recruitment completed in landmark Tourette syndrome study Pressreleaser Ladda ner | Visa Stäng
2022-10-06 Asarina Pharma Extensive new preclinical study significantly increases the Translatability of Asarina Pharma's findings on key stress mechanism implicated in Tourette Syndrome and OCD Pressreleaser Ladda ner | Visa Stäng
2022-10-06 Asarina Pharma Omfattande ny preklinisk studie ökar säkerheten av Asarina Pharmas resultat om en viktig stressmekanism involverad i Tourettes syndrom och OCD Pressreleaser Ladda ner | Visa Stäng
2022-08-25 Asarina Pharma Asarina Pharma AB (publ) Rapport för andra kvartalet 2022 släppt Rapporter Ladda ner | Visa Stäng
2022-08-25 Asarina Pharma Asarina Pharma AB (publ) Q2 2022 Report released Rapporter Ladda ner | Visa Stäng
Rapporter | 25 Aug 2022 | Asarina Pharma

Asarina Pharma AB (publ) Q2 2022 Report released

FINANCIAL HIGHLIGHTS

  • Total operating costs have been further reduced to SEK 4.0 million (Q2/2021: SEK 16.0 million.) This reflects that all resources are now being allocated to our phase IIa study in Tourette
  • Present funding still expected to cover the remaining cost of the Tourette study

R&D HIGHLIGHTS

TOURETTE SYNDROME

  • 70 % of patients have been recruited onto the Tourette study at two sites in Copenhagen
  • The dropout rate so far is unexpectedly low, at under 5%. To date no patients have dropped out from our largest `active dose’ group of those patients taking Sepranolone in addition to their regular treatment
  • During summer 2022 we recruited our first teenage patients (at the Danish National Center for Tourette at Herlev University Hospital)

  • Last-patient-last-visit remains scheduled for January 2023

  • Topline results to be released by the end of Q1 2023

CEO Peter Nordkild: ”If full clinical development is successful, Sepranolone will be the first endogenous, neuroendocrinological compound used to treat Tourette. As such it would represent an entirely new treatment modality – with no serious side effects. We would like to thank the ongoing commitment of our volunteer patients and our excellent teams at Bispebjerg and Herlev University hospitals in Copenhagen.”

To read the Report in full please visit: https://asarinapharma.com/investors/financial-reports/

Kommande händelser

17 May 2024 | Årligutdelning
15 Jun 2024 | Årsstämma 2023